Team:Duke

<!DOCTYPE html>

Novel Organoid-dependent Drug Efficacy Screening

Gliomas are the most common type of malignant tumor originating in the brain.

They comprise approximately

80% of all malignant brain tumors and

30% of all central nervous system tumors.

Globally, over 241,000 people die each year as a result of brain or nervous system cancer, with GBM being the most common form of diseases.

Glioma Survival Rates

Low Grade

Grade 1

Grade 2

Non-malignant

5-8 years

High Grade

Grade 3

Grade 4

3 years

12-18 months

There is no effective treatment option for the disease, and clinical treatment of GBM is limited by the lack of a scalable, physiologically relevant model for testing therapeutics.

To address these problems, we developed...

Novel Organoid-dependent Drug Efficacy Screening

NODES is a high-throughput organoid-based drug screening platform to characterize treatment efficacy in common glioma variants.

Our system is supported by
deep learning pipelines for organoid screening,
oncometabolite mathematical models,
and guidance from patients, clinicians, and other stakeholders

By recapitulating the brain microenvironment, NODES has the potential to accurately characterize drug responses, offering new hope to patients in their fight against this lethal disease.